Hims & Hers Health is trading 4.07% up at €26.06, potentially reflecting optimism over peptide-access rules.
- On October 15, Reuters confirmed U.S. officials submitted an interim peptide-compounding access policy for White House review; CNBC said Hims & Hers is among telehealth firms planning offerings if rules ease.
- Reports linked the news to the prior-session U.S. share rise. The policy remains under review, details are not public, no separate October 16 catalyst was identified, and no reliable volume figure was available.